Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Immunoprecise Antibodies Ltd IPA

ImmunoPrecise Antibodies Ltd. is a biotechnology company that leverages multi-omics modeling and complex artificial intelligence through a series of proprietary and patented technologies. The Company owns an integrated end-to-end suite of capabilities to support the development of therapeutic antibodies. It has several subsidiaries in North America and Europe including entities, such as Talem Therapeutics LLC, BioStrand BV, ImmunoPrecise Antibodies (Canada) Ltd. and ImmunoPrecise Antibodies (Europe) B.V. (collectively, the IPA Family). Its Contract Research Organizations (CRO) services include B cell Select; Phage Display; DeepDisplay; Abthena Bispecifics; LucinaTech Humanization; Affinity Maturation; Immunization, hybridoma, sequencing; rPEx protein manufacturing, and Cell line development. The Company utilizes custom antigen modeling, target analysis using Natural Language Processing and the HYFTTM analysis to lay the groundwork for the subsequent experimental phases.


NDAQ:IPA - Post by User

Post by wallpaper2on Apr 07, 2021 12:25pm
237 Views
Post# 32949726

In case you didn't read or notice them....

In case you didn't read or notice them....IPA's last 2 releases stated:
1-   27 Hamsters with the Covid19 virus were injected ONCE with a single dose of IPA's Antibody Cocktail and all 27 were clear within 3-4 days.
2-   Healthy Hamsters were given a single injection of IPA's newest Antibody Cocktail. The Hamsters were then directly exposed or given the Brazilian, South African and UK mutations/ variants of the Covid 19 virus. Not one Hamster became sick or contracted the Virus. 
Hamsters are invivo or living organisms like Humans.

Do you think this went unnoticed by the worlds Pharmaceutical Industry? Do you think IPA could be in negotiations with various Pharmas?  Hopefully they are and IPA soon trades in the $150-500.00 share price range where they belong. A Nasdaq stock like this one with only 19mil shs o/s is ridiculous.
<< Previous
Bullboard Posts
Next >>